How to appeal a CareFirst BCBS autoimmune cytopenias (itp + aiha) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for autoimmune cytopenias (itp + aiha)

Cited policy: BCBS Enjaymo (Sutimlimab-jome) Cold-Agglutinin Disease PA

Confirmed cold-agglutinin disease (DAT C3+ pattern, cold-agglutinin titer >=64 at 4 deg C, evidence of hemolysis — Hgb <=10 g/dL, elevated LDH, low haptoglobin, indirect hyperbilirubinemia). Symptomatic hemolysis or transfusion need within prior 6 mo. Adult >=18. Vaccinated against encapsulated organisms (meningococcal, pneumococcal, Hib) >=2 wk prior. Reauth 6 mo with hemoglobin and transfusion outcome.

How CareFirst BCBS denies autoimmune cytopenias (itp + aiha) — and how to counter it

Where CareFirst BCBS pushes back: 1) Must trial rituximab first; 2) Must trial steroids first; 3) Insufficient hemolysis severity.

Counter-arguments that hold up: Hill et al. International consensus for cold AIHA (BJH 2024) + Berentsen review supports sutimlimab as targeted classical-complement C1s blockade. CARDINAL (Roth NEJM 2021;384:1323-1334) — open-label, 54% composite response in recently-transfused CAD. CADENZA (Roth Blood 2022;140:980-991) — randomized placebo-controlled, composite primary endpoint met by 73% sutimlimab vs 15% placebo. CADENZA Part B (eClinicalMedicine 2024) confirmed durability. For patients with thrombosis / TIA history (CAD doubles thromboembolism risk per Broome Blood 2020) or transfusion dependence, do NOT delay sutimlimab. Steroids inappropriate first-line for CAD per BSH 2017 + Hill 2024 (low response, high toxicity). Rituximab response in CAD ~50% with months-long onset — sutimlimab acts within 1-3 wk.

What CareFirst BCBS typically denies for autoimmune cytopenias (itp + aiha)

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For autoimmune cytopenias (itp + aiha), expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the autoimmune cytopenias (itp + aiha) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Steroids (pred / dex)
• IVIG
• Anti-D (WinRho)
• Rituximab (off-label)
• Promacta (eltrombopag)
• Nplate (romiplostim)

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.